Next Article in Journal
The Microbiota/Host Immune System Interaction in the Nose to Protect from COVID-19
Next Article in Special Issue
The Role of Oxidative Stress in Cardiovascular Aging and Cardiovascular Diseases
Previous Article in Journal
Independent Evolution of Sex Chromosomes in Eublepharid Geckos, A Lineage with Environmental and Genotypic Sex Determination
Review

Cardiotoxicity of Novel Targeted Hematological Therapies

1
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Baronissi, 84081 Salerno, Italy
2
Clinical Pharmacology, University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, 84131 Salerno, Italy
3
IRCCS Neuromed (Mediterranean Neurological Institute), 86077 Pozzilli, Italy
4
Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi D’Aragona”, 84131 Salerno, Italy
*
Author to whom correspondence should be addressed.
Life 2020, 10(12), 344; https://doi.org/10.3390/life10120344
Received: 9 November 2020 / Revised: 9 December 2020 / Accepted: 10 December 2020 / Published: 11 December 2020
Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways important not only in cancer cells but also in myocytes. For example, Bruton’s tyrosine kinase (BTK) inhibitors interfere with class I phosphoinositide 3-kinase isoforms involved in cardiac hypertrophy, contractility, and regulation of various channel forming proteins; thus, off-target effects of BTK inhibitors are associated with increased frequency of arrhythmias, such as atrial fibrillation, compared to standard chemotherapy. In this review, we summarize current knowledge of cardiotoxic effects of targeted therapies used in hematology. View Full-Text
Keywords: cardiotoxicity; targeted therapy; adverse reactions; hematology cardiotoxicity; targeted therapy; adverse reactions; hematology
Show Figures

Figure 1

MDPI and ACS Style

Giudice, V.; Vecchione, C.; Selleri, C. Cardiotoxicity of Novel Targeted Hematological Therapies. Life 2020, 10, 344. https://doi.org/10.3390/life10120344

AMA Style

Giudice V, Vecchione C, Selleri C. Cardiotoxicity of Novel Targeted Hematological Therapies. Life. 2020; 10(12):344. https://doi.org/10.3390/life10120344

Chicago/Turabian Style

Giudice, Valentina, Carmine Vecchione, and Carmine Selleri. 2020. "Cardiotoxicity of Novel Targeted Hematological Therapies" Life 10, no. 12: 344. https://doi.org/10.3390/life10120344

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop